CureVac Revenue 2021-2021 | CVAC
CureVac revenue from 2021 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
| CureVac Annual Revenue (Millions of US $) |
|
|---|---|
| 2021 | $116 |
| 2020 | $56 |
| 2019 | $ |
| CureVac Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2021-12-31 | |
| 2021-09-30 | |
| 2020-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $3.370B | $0.116B |
| CureVac B.V. is a clinical-stage biopharmaceutical company. It engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102. CureVac B.V. is based in Germany. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $163.981B | 9.98 |
| Bio-Rad Laboratories (BIO.B) | United States | $15.121B | 32.79 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $9.996B | 0.00 |
| QIAGEN (QGEN) | Netherlands | $9.982B | 15.76 |
| Ginkgo Bioworks Holdings (DNA) | United States | $4.276B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $1.424B | 6.09 |
| Arcus Biosciences (RCUS) | United States | $1.353B | 34.31 |
| Myovant Sciences (MYOV) | United Kingdom | $0.930B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.444B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.355B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.299B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.138B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.118B | 24.20 |
| SQZ Biotechnologies (SQZ) | United States | $0.090B | 0.00 |
